Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| ES Clinical Research | UNKNOWN |
| Ipsen | INDUSTRY |
| Astellas Pharma Inc | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with prostate cancer.
It also aims to analyze the diagnostic approaches and management strategies used in the care of these patients in Algeria.
This is a descriptive, cross-sectional clinical study including patients with histologically and/or biologically confirmed prostate cancer who are being followed in the participating centers. This study planned to enroll 500 patients.
Data will be collected from medical records and structured patient interviews (≈30 minutes). A standardized electronic case report form (eCRF) will be used to ensure completeness and reliability of the data. The variables studied will include sociodemographic data, medical history, clinical and biological characteristics of the disease, diagnostic examinations performed, and the therapeutic strategies implemented. All information will be anonymized and used exclusively for research purposes.
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Socio-demographic characteristics of patients with prostate cancer in Algeria | Frequency (%) of sociodemographic characteristics of patients with prostate cancer in Algeria, including age at diagnosis, marital status, and socioeconomic level. | At Baseline ( Initial visit ) |
| Personal and family history of cancer | Frequency (%) of patients with personal and family history of cancer. | At Baseline (Initial Visit) |
| Environmental and occupational exposures | Frequency (%) of patients with environmental or occupational exposures. | At Baseline (Initial visit) |
| Smoking history | Frequency (%) of patients according to smoking status (current, former, never). | At Baseline (Initial visit) |
| Alcohol consumption | Frequency (%) of patients according to alcohol consumption (yes/no). | At Baseline (Initial visit) |
| Initial symptoms and circumstances of diagnosis | Frequency (%) of patients according to type of initial symptoms and circumstances of diagnosis. | At Baseline (Initial visit) |
| International Prostate Symptom Score (IPSS) | Distribution of patients according to the International Prostate Symptom Score (IPSS) at baseline. The IPSS is a validated questionnaire assessing the severity of lower urinary tract symptoms, with a total score ranging from 0 to 35, where higher scores indicate more severe (worse) symptoms. |
| Measure | Description | Time Frame |
|---|---|---|
| Diagnosis by PSA testing | % of patients diagnosed by PSA testing. | At Baseline (Initial visit) |
| Diagnosis by imaging | % of patients diagnosed by imaging. |
Not provided
Inclusion Criteria:
Non Inclusion Criteria:
Not provided
Not provided
Not provided
Patients with histologically and/or biologically confirmed prostate cancer, followed in the participating centers.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| BOUNEDJAR ADDA, Professor | Contact | +213 25 20 90 72 | a_bounedjar@yahoo.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CAC Adrar - Oncology Department | Not yet recruiting | Adrar | Algeria | 01000 | Algeria |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| At Baseline (Initial visit) |
| Evolutionary status of patients | Frequency (%) of patients according to disease status (in remission or with disease progression). | At Baseline (Initial visit) |
| At Baseline (Initial visit) |
| Diagnosis by biopsy | % of patients diagnosed by biopsy. | At Baseline (Initial visit) |
| Time from symptom onset to first medical consultation | Median time (in days) between onset of first symptoms and first medical consultation. | At Baseline (Initial visit) |
| Time from first consultation to confirmed diagnosis | Median time (in days) between first medical consultation and confirmed diagnosis. | At Baseline (Initial visit) |
| Patients discussed in multidisciplinary team meetings | % of patients discussed in tumor boards / multidisciplinary team meetings. | At Baseline (Initial visit) |
| Initial treatment: Surgery | % of patients receiving surgery as initial treatment. | At Baseline (Initial visit) |
| Initial treatment: Radiotherapy | % of patients receiving radiotherapy as initial treatment. | At Baseline (Initial visit) |
| Initial treatment: Hormone therapy | % of patients receiving hormone therapy as initial treatment. | At Baseline (Initial visit) |
| Initial treatment: Active surveillance | % of patients under active surveillance as initial management. | At Baseline (Initial visit) |
| Time from diagnosis to treatment initiation | Median time (in days) between diagnosis and treatment initiation. | At Baseline (Initial visit) |
| Specialty of physician initiating treatment | Medical specialty of the physician initiating treatment (urologist, oncologist, etc.). | At Baseline (Initial visit) |
| Adverse events | Frequency of adverse events by system/organ class and distribution according to severity grades (CTCAE grades 1 to 5). | At Baseline (Initial visit) |
| CAC Adrar - Radiotherapy Department | Not yet recruiting | Adrar | Algeria | 01000 | Algeria |
|
| CAC BLIDA - Oncology Department | Recruiting | Algiers | Algeria | 16000 | Algeria |
|
| Centre Pierre et Marie Curie - Oncology Department | Recruiting | Algiers | Algeria | 16000 | Algeria |
|
| Centre Pierre et Marie Curie - Radiology Department | Recruiting | Algiers | Algeria | 16000 | Algeria |
|
| CHU Bab El Oued | Recruiting | Algiers | Algeria | 16000 | Algeria |
|
| CHU Béni Messous - Oncology Departement | Recruiting | Algiers | Algeria | 16000 | Algeria |
|
| EPH ROUIBA - Oncology Department | Recruiting | Algiers | Algeria | 16000 | Algeria |
|
| CAC Annaba - Oncology Departement | Recruiting | Annaba | Algeria | 23000 | Algeria |
|
| CAC Annaba - Radiotherapy Department | Recruiting | Annaba | Algeria | 23000 | Algeria |
|
| CAC Annaba - Urology Departement | Recruiting | Annaba | Algeria | 23000 | Algeria |
|
| CAC Bida - Radiotherapy Department | Recruiting | Blida | Algeria | 09000 | Algeria |
|
| CAC BLIDA - Urology Department | Recruiting | Blida | Algeria | 09000 | Algeria |
|
| CHU Constantine - Oncology Departement | Recruiting | Constantine | Algeria | 25000 | Algeria |
|
| EH Constantine - Oncology Departement | Recruiting | Constantine | Algeria | 25000 | Algeria |
|
| EPH Mostaghanem - Oncology Department | Recruiting | Mostaganem | Algeria | 27000 | Algeria |
|
| CAC ORAN - Oncology Department | Recruiting | Oran | Algeria | 31000 | Algeria |
|
| CAC ORAN - Radiotherapy Department | Recruiting | Oran | Algeria | 31000 | Algeria |
|
| EHU ORAN - Oncology Department | Not yet recruiting | Oran | Algeria | 31000 | Algeria |
|
| EHU ORAN - Urology Department | Recruiting | Oran | Algeria | 31000 | Algeria |
|
| CAC Sétif - Oncology Departement | Recruiting | Sétif | Algeria | 19000 | Algeria |
|
| CAC Sétif - Radiotherapy Department | Recruiting | Sétif | Algeria | 19000 | Algeria |
|
| EPH Sidi Ghilès - Oncology Department | Recruiting | Tipasa | Algeria | 42000 | Algeria |
|
| CAC Draa Ben Khedda - Radiotherapy Departement | Recruiting | Tizi Ouzou | Algeria | 15000 | Algeria |
|
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| D004194 | Disease |
| D000230 | Adenocarcinoma |
| D009369 | Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided